Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Carcinoma Neuroendocrine Skin
- Merkel Cell Carcinoma
- Merkel Cell Carcinoma, Stage I
- Merkel Cell Carcinoma, Stage II
- Merkel Cell Carcinoma, Stage III
- Neuroendocrine Tumors
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: Double-blindPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The I-MAT trial is a phase II, prospective, randomised, placebo-controlled, multi-institutional trial for patients with stage I-III Merkel cell carcinoma (MCC). Participants on the trial will receive either avelumab or placebo for 6 months. The primary aim of the I-MAT trial is to develop an effecti...
The I-MAT trial is a phase II, prospective, randomised, placebo-controlled, multi-institutional trial for patients with stage I-III Merkel cell carcinoma (MCC). Participants on the trial will receive either avelumab or placebo for 6 months. The primary aim of the I-MAT trial is to develop an effective, well-tolerated adjuvant immunotherapy regimen for patients with stage I-III MCC, following local and regional treatment options which includes surgery and/or radiotherapy.
Tracking Information
- NCT #
- NCT04291885
- Collaborators
- Not Provided
- Investigators
- Study Chair: Wen Xu, MBBS, FRACP Princess Alexandra Hospital
Get Well Soon